NewAmsterdam Pharma Company NAMS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $22.5M-50.6% | $45.56M+223% | $14.09M-86.3% | $102.69M— | ||
| $141.83M-6.3% | $151.41M-5.0% | $159.42M+83.8% | $86.74M+199% | ||
| $106.35M+51.0% | $70.45M+87.2% | $37.63M+92.9% | $19.51M+225% | ||
| $248.19M+11.9% | $221.85M+12.6% | $197.06M+85.5% | $106.25M+204% | ||
| -$225.68M-28.0% | -$176.29M+3.6% | -$182.97M-5,044% | -$3.56M+89.8% | ||
| -1,002.9%-616pp | -386.9%+912pp | -1,298.6%-1,295pp | -3.5%— | ||
| $13.14M+299% | -$6.6M-230% | $5.06M+152% | -$9.75M-671% | ||
| -$203.82M+15.6% | -$241.6M-36.6% | -$176.91M-682% | -$22.63M+45.8% | ||
| —— | —— | $27K— | —— | ||
| -$203.82M+15.6% | -$241.6M-36.5% | -$176.94M-682% | -$22.63M+45.8% | ||
| -905.7%-375pp | -530.3%+726pp | -1,255.8%-1,234pp | -22%— | ||
| -$1.73+33.5% | -$2.60-20.9% | -$2.15-80.7% | -$1.19+68.8% | ||
| -$225.46M-28.0% | -$176.18M+3.7% | -$182.92M-5,056% | -$3.55M+89.9% | ||
| -1,001.9%-615pp | -386.7%+912pp | -1,298.2%-1,295pp | -3.5%— | ||
| -$225.68M-28.0% | -$176.29M+3.6% | -$182.97M-5,044% | -$3.56M+89.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's income statement data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.